Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma (MMR-PET-22-04)

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Enrolling

Conditions: Multiple Myeloma

Study type: Observational

Funder types: Other

Identifiers

NCT06659276

IRCCS S.Orsola Malpighi

Details and patient eligibility

About

The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.

Enrollment: 83 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase

  • Patients who have signed the informed consent form

Exclusion criteria

• Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years

  • Age < 18 years
  • Women who are breastfeeding or pregnant
  • Patients with metal implants or devices that constitute an absolute contraindication for MRI
  • Patients with severe claustrophobia
  • Patients with bone pain that prevents prolonged maintenance of the supine position

Trial design

83 participants in 1 patient group

patients with new diagnosis of symptomatic multiple myeloma

Description:

fdg pet/CT and Whole body MRI with DWI